Stolwyk, K., & Lee, I. (2025). Rapid progression of amyotrophic lateral sclerosis after initiation of GLP-1 agonist: a case report. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 1–3. https://doi.org/10.1080/21678421.2024.2446847

Lee, I., Vestrucci, M., Lee, S., Rosenbaum, M., & Mitsumoto, H. (2024). Blood glycated hemoglobin level is not associated with disease progression in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 1–5. https://doi.org/10.1080/21678421.2024.2407409

Lee, I., Garret, M. A., Wuu, J., Harrington, E. A., Berry, J. D., Miller, T. M., Harms, M., Benatar, M., & Shneider, N. (2024). Body mass index is lower in asymptomatic C9orf72 expansion carriers but not in SOD1 pathogenic variant carriers compared to gene negatives. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 1–8. https://doi.org/10.1080/21678421.2024.2396831

Roggenbuck, J., Kaschalk, M., Eustace, R., Vicini, L., Gokun, Y., Harms, M. B., & Kolb, S. J. (2024). The Answer ALS return of results study: Answering the duty to disclose. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 1–8. https://doi.org/10.1080/21678421.2024.2385004

Dratch, L., Kinnamon, D. D., Harrington, E. A., Goldman, J., Fong, J. C., Jones, T., Uhlmann, W. R., & Roggenbuck, J. (2024). Response to “assessment of risk of ALS conferred by the GGGGCC hexanucleotide expansion in C9orf72 among first-degree relatives of patients with ALS carrying the repeat expansion.” Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 1–3. https://doi.org/10.1080/21678421.2024.2362854

Dilliott, A. A., Al Nasser, A., Elnagheeb, M., Fifita, J., Henden, L., Keseler, I. M., Lenz, S., Marriott, H., Mccann, E., Mesaros, M., Opie-Martin, S., Owens, E., Palus, B., Ross, J., Wang, Z., White, H., Al-Chalabi, A., Andersen, P. M., … Benatar, M. (2023). Clinical testing panels for ALS: global distribution, consistency, and challenges. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 24(5–6), 420–435. https://doi.org/10.1080/21678421.2023.2173015

Shefner, J. M., Al-Chalabi, A., Andrews, J. A., Chio, A., De Carvalho, M., Cockroft, B. M., Corcia, P., Couratier, P., Cudkowicz, M. E., Genge, A., Hardiman, O., Heiman-Patterson, T., Henderson, R. D., Ingre, C., Jackson, C. E., Johnston, W., Lechtzin, N., Ludolph, A., Maragakis, N. J., … Rudnicki, S. A. (2023). COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 24(5–6), 523–534. https://doi.org/10.1080/21678421.2023.2216223

Mitsumoto, H., Jang, G., Lee, I., Simmons, Z., Sherman, A. V., Heitzman, D., Sorenson, E., Cheung, K., Andrews, J., Harms, M., Shneider, N. A., Santella, R., Paganoni, S., Ajroud-Driss, S., Fernandes, J. A. M., Burke, K. M., Gwathmey, K., Habib, A. A., … Maragakis, N. J. (2022). Primary lateral sclerosis natural history study – planning, designing, and early enrollment. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 24(5–6), 394–404. https://doi.org/10.1080/21678421.2022.2161912

McMillan, C. T., Wuu, J., Rascovsky, K., Cosentino, S., Grossman, M., Elman, L., Quinn, C., Rosario, L., Stark, J. H., Granit, V., Briemberg, H., Chenji, S., Dionne, A., Genge, A., Johnston, W., Korngut, L., Shoesmith, C., Zinman, L., … Benatar, M. (2022). Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 23(7–8), 517–526. https://doi.org/10.1080/21678421.2022.2039713